 July 27, 2006
|
An HIV Drug Says Goodbye
In a letter sent to doctors late last month, Roche Pharmaceuticals announced that it will be ending the sale and distribution of Hivid® (zalcitabine, also known as ddC), a nucleoside reverse transcriptase inhibitor (NRTI) originally approved in 1992.
|
|
|
July 26, 2006
|
Risk Factors Identified in HIV-HCV Steatosis
In patients co-infected with HIV and hepatitis C virus (HCV), hepatic steatosis is prevalent and associated with nucleoside analogue use, HCV genotype 3 infection and fibrosis, clinicians from Massachusetts and Rhode Island report.
|
|
|
July 24, 2006
|
I Forgot
Perfect adherence - taking medications as prescribed without missing doses - is considered to be one of the most important factors in terms of reducing the risk of HIV drug resistance and maximizing the life-saving benefits of treatment. But for many HIV-positive people taking daily doses, adherence can be a major challenge.
|
|
|
Growth Hormone Helps Lipo Lipids
Restoration of growth hormone levels to normal improves lipid kinetics in patients with HIV lipodystrophy syndrome (HLS), according to a report in the July issue of the American Journal of Clinical Nutrition.
|
|
|
| July 20, 2006
|
July 18, 2006
|
Doctors, Patients Disagree on Resistance Concerns
HIV-positive people and their doctors agree that anti-HIV drug resistance is one of the most challenging issues in HIV care today. However, their degree of concern is dramatically different, according to a survey commissioned by the American Academy of HIV Medicine (AAHIVM).
|
|
|
July 17, 2006
|
Short-Term Treatment Curbs Vertical Transmission
In a resource-limited setting, short courses of the nucleoside analogues stavudine, didanosine or zidovudine can help prevent mother-to-child transmission of HIV, according to researchers in South Africa.
|
|
|
July 13, 2006
|
HIV Reservoir Decays Slowly In Children
Although there is a rapid drop in HIV levels in infected children after initial highly active antiretroviral therapy (HAART), further decay is less rapid, according to Italian and UK researchers.
|
|
|
July 12, 2006
|
One-Pill, Once-Daily Combo Approved
Bristol-Myers Squibb and Gilead Sciences announced on July 12 that they have received U.S. Food and Drug Administration (FDA) clearance to begin selling Atripla? (pronounced "uh-TRIP-luh"), their long-awaited fixed-dose combination tablet containing Sustiva® (efavirenz) and Truvada® (tenofovir and emtricitabine).
|
|
|
| July 11, 2006
|
July 07, 2006
|
Anti-CD4 Antibody Synergistic With Enfuvirtide Against HIV-1
The humanized monoclonal anti-CD4 antibody TNX-355 is synergistic with the fusion inhibitor enfuvirtide (T-20) in blocking HIV-1 entry into target cells in vitro, according to a report in the June issue of Antimicrobial Agents and Chemotherapy.
|
|
|
July 06, 2006
|
T. Gondii Prophylaxis Can Stop After Immune Restoration
HIV patients responding to highly active antiretroviral therapy (HAART)
do not appear to need prophylaxis against Toxoplasma gondii infection,
Spanish researchers report in the July 1st issue of Clinical Infectious
Diseases.
|
|
|
July 05, 2006
|
New Aptivus Warning: Bleeding in the Brain
he U.S. Food and Drug Administration announced on June 30 that it is working with Boehringer Ingelheim, the manufacturer of Aptivus® (tipranavir), to inform healthcare providers about a potentially serious health problem that has been in seen in patients taking the protease inhibitor.
|
|
|
July 04, 2006
|
Genetic Screening Cuts Abacavir Reactions
In a study of HIV-infected patients living in Western Australia,
screening for HLA-B*5701, the major factor implicated in abacavir
hypersensitivity, was useful in preventing the side effect.
|
|
|
July 03, 2006
|
Europe Approves New Kaletra
Abbott Laboratories Inc. said on Monday the European Commission had
approved a new formulation of its HIV protease inhibitor Kaletra
(lopinavir + ritonavir) that will allow patients to take fewer pills
and will not need to be refrigerated.
|
|
|
|
